Akums Drugs and Pharmaceutical (AKUMS) - Net Assets
Based on the latest financial reports, Akums Drugs and Pharmaceutical (AKUMS) has net assets worth Rs31.68 Billion INR (≈ $342.65 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs51.59 Billion ≈ $557.96 Million USD) and total liabilities (Rs19.91 Billion ≈ $215.30 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Akums Drugs and Pharmaceutical liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs31.68 Billion |
| % of Total Assets | 61.41% |
| Annual Growth Rate | 69.83% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 149.84 |
Akums Drugs and Pharmaceutical - Net Assets Trend (2022–2025)
This chart illustrates how Akums Drugs and Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Akums Drugs and Pharmaceutical for the complete picture of this company's asset base.
Annual Net Assets for Akums Drugs and Pharmaceutical (2022–2025)
The table below shows the annual net assets of Akums Drugs and Pharmaceutical from 2022 to 2025. For live valuation and market cap data, see Akums Drugs and Pharmaceutical market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs30.64 Billion ≈ $331.32 Million |
+325.21% |
| 2024-03-31 | Rs7.20 Billion ≈ $77.92 Million |
-0.40% |
| 2023-03-31 | Rs7.23 Billion ≈ $78.23 Million |
+15.71% |
| 2022-03-31 | Rs6.25 Billion ≈ $67.61 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Akums Drugs and Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 228.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs18.29 Billion | 60.04% |
| Common Stock | Rs306.21 Million | 1.00% |
| Other Components | Rs11.87 Billion | 38.95% |
| Total Equity | Rs30.47 Billion | 100.00% |
Akums Drugs and Pharmaceutical Competitors by Market Cap
The table below lists competitors of Akums Drugs and Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
|
$906.22 Million |
|
I.E.S Holdings Ltd
TA:IES
|
$906.24 Million |
|
Sipef NV
BR:SIP
|
$906.31 Million |
|
Metalurgica Gerdau S.A
SA:GOAU3
|
$906.45 Million |
|
Zhejiang Zhongxin Fluoride Materials Co Ltd Class A
SHE:002915
|
$906.16 Million |
|
MAHLE Metal Leve S.A
SA:LEVE3
|
$905.57 Million |
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
$905.51 Million |
|
Eckert & Ziegler Strahlen- und Medizintechnik AG
F:EUZ
|
$905.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akums Drugs and Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,094,980,000 to 30,470,140,000, a change of 23,375,160,000 (329.5%).
- Net income of 3,381,760,000 contributed positively to equity growth.
- New share issuances of 6,373,700,000 increased equity.
- Other factors increased equity by 13,619,700,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs3.38 Billion | +11.1% |
| Share Issuances | Rs6.37 Billion | +20.92% |
| Other Changes | Rs13.62 Billion | +44.7% |
| Total Change | Rs- | 329.46% |
Book Value vs Market Value Analysis
This analysis compares Akums Drugs and Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.85x to 2.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | Rs39.52 | Rs547.30 | x |
| 2023-03-31 | Rs45.57 | Rs547.30 | x |
| 2024-03-31 | Rs45.08 | Rs547.30 | x |
| 2025-03-31 | Rs203.66 | Rs547.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akums Drugs and Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.10%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.31%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 1.35x
- Recent ROE (11.10%) is above the historical average (-4.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -40.60% | -6.92% | 1.19x | 4.93x | Rs-3.15 Billion |
| 2023 | 13.23% | 2.73% | 1.06x | 4.55x | Rs231.36 Million |
| 2024 | -0.57% | -0.10% | 1.14x | 4.96x | Rs-749.85 Million |
| 2025 | 11.10% | 8.31% | 0.99x | 1.35x | Rs334.75 Million |
Industry Comparison
This section compares Akums Drugs and Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $25,653,480,069
- Average return on equity (ROE) among peers: 14.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akums Drugs and Pharmaceutical (AKUMS) | Rs31.68 Billion | -40.60% | 0.63x | $906.19 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Akums Drugs and Pharmaceutical
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and co… Read more